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Abstract Neuromyelitis optica (NMO, Devic’s syn-
drome), long considered a clinical variant of multiple
sclerosis, is now regarded as a distinct disease entity. Major
progress has been made in the diagnosis and treatment of
NMO since aquaporin-4 antibodies (AQP4-Ab; also termed
NMO-IgG) were first described in 2004. In this review, the
Neuromyelitis Optica Study Group (NEMOS) summarizes
recently obtained knowledge on NMO and highlights new
developments in its diagnosis and treatment, based on
current guidelines, the published literature and expert dis-
cussion at regular NEMOS meetings. Testing of AQP4-Ab
is essential and is the most important test in the diagnostic
work-up of suspected NMO, and helps to distinguish NMO
from other autoimmune diseases. Furthermore, AQP4-Ab
testing has expanded our knowledge of the clinical pre-
sentation of NMO spectrum disorders (NMOSD). In
addition, imaging techniques, particularly magnetic reso-
nance imaging of the brain and spinal cord, are obligatory
in the diagnostic workup. It is important to note that brain
lesions in NMO and NMOSD are not uncommon, do not
rule out the diagnosis, and show characteristic patterns.
Other imaging modalities such as optical coherence
tomography are proposed as useful tools in the assessment
of retinal damage. Therapy of NMO should be initiated
early. Azathioprine and rituximab are suggested as first-
line treatments, the latter being increasingly regarded as an
established therapy with long-term efficacy and an
acceptable safety profile in NMO patients. Other immu-
nosuppressive drugs, such as methotrexate, mycophenolateMembers of Neuromyelitis Optica Study Group (NEMOS) are listed
in the appendix.
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mofetil and mitoxantrone, are recommended as second-line
treatments. Promising new therapies are emerging in the
form of anti-IL6 receptor, anti-complement or anti-AQP4-
Ab biologicals.
Keywords Neuromyelitis optica  Differential
diagnosis  Diagnostic tests  Therapy
NEMOS
The Neuromyelitis Optica Study Group (NEMOS; see
http://www.nemos-net.de) was initiated in 2008 by neu-
rologists at 25 German university and academic teaching
hospitals as an open-access network to improve the care
of patients with neuromyelitis optica (NMO). Since then,
the group has organized a number of national and
international meetings and symposia on NMO, collected
and analyzed data on epidemiological, clinical, and
magnetic resonance imaging (MRI) characteristics of
NMO in a large German cohort [1], and published rec-
ommendations on the diagnosis and treatment of NMO
in Germany [2]. In the following report, these recom-
mendations are updated to reflect the most recent liter-
ature in the field and current scientific knowledge. The
2010 guidelines of the European Federation of Neuro-
logical Societies (EFNS) on the diagnosis and manage-
ment of NMO, guidelines published by an international
expert group [3], and the evidence-based guidelines on
clinical evaluation and treatment of transverse myelitis
published by the Therapeutics and Technology Assess-
ment Subcommittee of the American Academy of Neu-
rology can also be referred to for additional information
[4, 5].
Introduction
Neuromyelitis optica is an immune-mediated chronic
inflammatory disease of the central nervous system (CNS)
[1, 6, 7]. NMO was first described in the 19th century and
was long considered a clinical variant of multiple sclerosis
(MS) [8–13]. Clinically, it presents with optic neuritis (ON)
and myelitis, often characterized by poor or no recovery.
Imaging typically shows longitudinally extensive lesions
spanning three or more vertebral segments. Histopatho-
logically, NMO is characterized by astrocytic damage,
demyelination, neuronal loss, and often pronounced
necrosis [14–16]. The discovery of perivascular antibody
and complement deposition within active lesions and the
subsequent discovery of specific autoantibodies (aquapo-
rin-4 antibodies, AQP4-Ab; also termed NMO-IgG) in the
serum of NMO patients indicated that humoral immunity is
involved in the majority of cases. AQP4-Ab-positive NMO
is now distinguished from MS as an independent disease
entity [17–27]. Accordingly, serological identification of
NMO-IgG has also been included as an additional criterion
in all diagnostic criteria for NMO currently in use [2, 4, 28,
29].
Epidemiology
Solid data on the incidence and prevalence of NMO are
lacking. Its prevalence is estimated to range from less than
1 to 4.4/100.000 in the Western world [31–33]. In the past,
many patients ([20 %) with NMO were misdiagnosed with
MS, especially before NMO-IgG testing became widely
available [1]. Notably more women than men have NMO
(ratio 9:1, compared with just 2:1 in MS) [1, 34]. The
median age at onset, 39 years, is approximately 10 years
higher than in MS [1, 30]. However, cases of onset during
childhood and in the elderly have been described [1, 35–
38]. NMO takes either a relapsing or a monophasic course,
with the former predominating (approximately 80–90 % of
cases) [1, 30]. Compared with MS, AQP4-Ab-positive
NMO is more frequently associated with other autoimmune
diseases such as myasthenia gravis, systemic lupus ery-
thematosus, Sjo¨gren’s syndrome, celiac disease, and sar-
coidosis [1, 39–52]. In up to 20–30 % of cases, NMO
attacks are preceded by infection or vaccination [1, 7]. Age
at onset and genetic factors may influence the clinical
outcome [53].
Only few reports on the influence of pregnancies in
NMO exist. Two studies reported an increase in relapse
rate in the first 3 or 6 months, respectively, post partum
[54, 55].
Diagnostic criteria
According to the criteria proposed by Wingerchuk et al.
[28] in 2006, a diagnosis of NMO can be made with high
specificity if, in addition to a history of at least one episode
of ON and one episode of myelitis, two of the following
three supporting criteria are met:
1. Contiguous spinal cord MRI lesion extending over
three or more vertebral segments
2. Brain MRI not meeting Paty’s diagnostic criteria for
MS1 [56] at disease onset.2
1 Four or more white matter lesions, or more than three white matter
lesions if one of these is located in the periventricular region.
2 If no cranial MRI was performed at disease onset, or the findings
are unknown, the earliest available MRI should be used [28].
2 J Neurol (2014) 261:1–16
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3. NMO-IgG seropositive status3
Of note, the sensitivity and specificity of these criteria
[28] were defined using brain MRI at disease onset as first
preference. If the first scan available was taken at a later
time and was negative for MS, it was assumed that the
onset scan would also have been negative. By contrast, the
authors did not indicate whether the brain MRI criterion
should be applied at all if the first available scan was taken
at a later time and met MS criteria. However, we believe
that the diagnostic criteria proposed by Wingerchuk et al.
should, in general, not be applied to rule out NMO if any of
the paraclinical procedures required to evaluate the three
supporting criteria were not performed. Of course, a
diagnosis of NMO can be made if the index events and any
two of the three supporting criteria are met, even though
information on the third supporting criterion is not
available.
More broadly, those criteria should be primarily used to
make, rather than to exclude, a diagnosis of NMO, because
brain lesions and (far more rarely) short spinal cord
lesions—individually or combined—may in fact be present
in patients with otherwise typical NMO (as confirmed by
AQP4-Ab seropositivity and/or occurrence of longitudinal
extensive transverse myelitis (LETM) in the later disease
course in these patients) [1].
‘‘NMO-spectrum disorder’’—abortive and atypical
manifestations
AQP4-Ab have been demonstrated in patients with condi-
tions other than classical NMO, including isolated LETM,
as defined by lesions spanning over more than three seg-
ments, monophasic or recurrent isolated ON, and certain
types of brainstem encephalitis (particularly if the dien-
cephalon or the medulla oblongata is involved) [57–59].
Brainstem manifestations frequently include intractable
hiccups or vomiting, symptomatic narcolepsy, and neuro-
endocrine dysfunctions [58–60], and may also precede ON
or myelitis [1, 61–63]. It has been suggested that posterior
reversible encephalopathy syndrome might also present in
the context of NMO [64]. Recently, olfactory dysfunction
has been described in patients with NMO [65]. Whether
AQP4-Ab causes damage outside the CNS (e.g., placenta
[1–3], stomach [4], muscle [5, 6], or inner ear [7]) is cur-
rently under investigation.
In children, an even broader spectrum of encephalitic
manifestations has been described, in particular regarding
seizures [36–38]. In a German cohort, 152 of 175 patients
(87 %) did not present at disease onset with simultaneous
myelitis and bilateral ON, but with isolated (mostly uni-
lateral) ON, isolated myelitis, or brainstem encephalitis.
Similarly, 89 of 106 patients (84 %) presented with abor-
tive or atypical symptoms in a British-Japanese cohort [1,
53]. As most of these patients later developed NMO, var-
ious groups have suggested classifying these symptoms—if
occurring in the context of AQP4-Ab seropositivity—as
‘high-risk syndromes for NMO’ (HRS) and referring to
AQP4-Ab-positive classical NMO and AQP4-Ab-positive
HRS as ‘NMO spectrum disorder’ (NMOSD) or ‘autoim-
mune AQP4 channelopathy’ [74–77]. The inconsistent use
of the term ‘NMOSD’ has recently been criticized [8].
Clinical evaluation when NMO is suspected
Medical history and physical examination
A detailed medical history is essential. The neurological
and physical examination should focus not only on the
primary symptoms, but also on disease indicators that
could suggest alternative diagnoses or concomitant auto-
immune disorders, which are frequently present in patients
with AQP4-Ab-positive NMO [1, 45, 47]. Special attention
should be paid to brainstem symptoms, neuropathic pain,
and painful tonic spasm [78], which have been shown to
occur more frequently in NMO than in MS, and which have
a demonstrated serious impact on quality of life [1, 58–63,
79, 80].
Basic laboratory tests
The following tests are recommended for exclusion of
differential diagnoses or confirmation of NMO-associated
diseases: differential blood count, coagulation, serum
chemistry, blood sedimentation, blood glucose, vitamin
B12 [81], folic acid, antibodies associated with connective
disorders (ANA/ENA, anti-ds-DNA antibodies, lupus
anticoagulant, antiphospholipid antibodies, ANCA, etc.
[45]), urine analysis and sediment, Treponema pallidum
hemagglutination assay, and paraneoplastic antibodies (in
particular, anti-CV2/CRMP5 [82] and anti-Hu). Based on
clinical presentation and cerebrospinal fluid (CSF) results,
analysis for copper deficiency (to exclude it as a cause of
myelopathy) and zinc poisoning (if suspected) should be
3 Detection of AQP4-Ab using recombinant methods can replace
immunohistochemical detection of NMO-IgG [18], provided that the
respective recombinant test has been demonstrated to yield equal or
better sensitivity and specificity in clinically well-defined and
sufficiently large patient and control collectives, and has been
successfully validated using an NMO-IgG-positive patient collective.
Of the testing systems described in the literature and currently
available for diagnosis, mainly cell-based assays meet these require-
ments. Alternatively, seropositivity for AQP4-Ab in two methodo-
logically independent immunoassays is considered by some to be a
valid substitute for NMO-IgG seropositivity (expert opinion).
J Neurol (2014) 261:1–16 3
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performed [83]. Moreover, recently, antibodies to myelin
oligodendrocyte glycoprotein (MOG) have been reported
in a subset of both adult and pediatric patients with (mostly
AQP4-Ab-negative) NMO [84–86]; however, the exact
diagnostic and therapeutic relevance of this finding is
currently investigated [87].
Detection of AQP4 antibodies
Several techniques are currently available to test for serum
AQP4-Ab and can be categorized according to whether
they are tissue-, cell-, or protein-based [18, 25, 88–97].
Using these serological tests, AQP4-Ab are detected in
60–90 % of patients who meet the clinical and radiologic
criteria for NMO. The specificity of these assays varies
between *90 and 100 %. So-called cell-based assays
using HEK293 cells transfected with recombinant, full-
length human AQP4 have shown higher sensitivity and
specificity than indirect immunofluorescence (IHC) [88,
90, 95, 98], enzyme-linked immunosorbent assays [95],
and, in particular, radioimmunoprecipitation assays [93].
The prevalence of AQP4-Ab seems to be higher in female
patients and in patients with relapsing disease [1, 99].
AQP4-Ab serum levels have been shown to be higher
during relapse than during remission [88, 95, 96, 98, 100,
101]. However, levels during relapse vary considerably
both inter- and intraindividually, with no apparent thresh-
old for relapse induction [100, 102]. AQP4-Ab remain
detectable in many cases during immunosuppressive
treatment (with the exception of plasma exchange), as long
as sufficiently sensitive assays are used [100]. Whenever
possible, however, AQP4-Ab testing should be performed
on samples taken prior to treatment commencement [100].
Re-testing initially seronegative patients during an acute
attack or a treatment-free interval may be advisable [38].
Routine testing of AQP4-IgM is currently not recom-
mended [103]. The diagnostic value of AQP4-Ab in the
CSF remains controversial [104, 105]. AQP4-IgG are rel-
atively stable over a period of at least a week at room
temperature or 4 C [106]; however, shipment on dry ice
may be advisable for low-titer or CSF samples.
While AQP4-Ab are potentially of high diagnostic and
therapeutic relevance, a critical need exists to challenge the
current clinical practice of AQP4-Ab testing, for the fol-
lowing reasons: (1) Due to the low incidence of AQP4-IgG-
positive NMO, the vast number of patients currently tested
for AQP4-Ab [107], the limited specificity of some diag-
nostic assays, and the insufficient number of controls
included in almost all past studies, the ratio of false-positive
to true-positive test results might be higher than generally
expected. This is even more problematic in patients pre-
senting with a first episode of isolated ON or brainstem
encephalitis, who are less frequently positive for AQP4-Ab.
(2) Assays with insufficient sensitivity, such as IHC, have
been broadly used in the past and are still partly in use.
False-negative results may lead to treatment with inter-
feron-beta or natalizumab for suspected MS; these two
drugs are thought to cause disease exacerbation or to have
no therapeutic benefit, respectively, in patients with NMO.
On the other hand, false-positive results might prompt
treatment with immunosuppressants with no established
efficacy in MS and potentially serious side effects. Manu-
facturer-independent, multicenter comparative trials that
include multiple assays as well as a sufficient number of
adequate controls (C1,000) are urgently required. Ideally,
AQP4-Ab test results should therefore be confirmed using a
second, methodologically independent assay with high
sensitivity and specificity, and, in the case of conflicting
results, a third assay. Moreover, repeat testing is recom-
mended in equivocal cases.
Cerebrospinal fluid diagnostics
Examination of CSF includes cell count, cytology, protein,
lactate, albumin CSF/serum ratio, IgG, IgA, and IgM CSF/
serum ratios, oligoclonal bands (OCB), and the MRZ
(measles, rubella, and varicella zoster virus) reaction.
Moderate pleocytosis (mostly lymphomonocytic) is often a
feature of NMO, and can be more prominent than in MS,
but usually less than in infectious myelitis [7, 108–111].
On the other hand white cell counts are normal in around
40 % of CSF samples during acute relapses in patients with
AQP4-Ab positive NMO [111]. Neutrophil (sometimes
also eosinophil) granulocytes are frequently detected and,
especially if present along with elevated lactate levels, may
lead to the incorrect diagnosis of infectious myelitis in
individual patients [111–113]. OCBs are positive in
approximately 30 % of cases [111]. Repeating the CSF
analysis can be useful for individual cases, since—unlike in
MS—most CSF alterations in NMO mainly present during
acute events and disappear during remission [111]. More-
over, an initial finding of OCB positivity followed by OCB
negativity later in the disease course is indicative of NMO
[104, 111, 114], but not MS. Testing for a positive MRZ
reaction (defined as intrathecal IgG synthesis against at
least two of the three pathogens) can be useful for differ-
entiating between NMO and MS, as it is frequently positive
in MS but not in NMO [1, 115]. More recently, concen-
trations of interleukin-6 (IL-6) and of the soluble IL-6
receptor (sIL-6R) were found to be higher in the CSF of
NMO patients than of MS patients, and these may prove to
be useful markers for differentiating NMO from other
demyelinating diseases [116–118]. Whether measurements
of glial fibrillary acidic protein (GFAP) in serum and/or
CSF are of differential diagnostic value in NMO remains to
be clarified [119–124].
4 J Neurol (2014) 261:1–16
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Electrophysiology
Visual evoked potentials, median and tibial somatosensory
evoked potentials, and motor evoked potentials should be
performed. Visual evoked potentials are frequently altered
in NMO [125, 126]. A recent study found prolonged P100
latencies in around 40 % and reduced amplitudes or
missing potentials in around 25 % of patients [125].
Imaging
Magnetic resonance imaging
Magnetic resonance imaging is the most important imaging
technique in the differential diagnosis of NMO. Imaging of
the entire CNS (cranial and spinal cord MRI) should
always be performed, regardless of the primary presenting
clinical signs and symptoms. Contrast agents are obliga-
tory, as are follow-up examinations. Predominantly central
longitudinally spinal cord lesions, usually extending over
three or more vertebral segments, are typical of NMO
[127]. These often, but not always, show contrast
enhancement for weeks up to months after the onset of
symptoms. Enhancement can be patchy and inhomoge-
neous. Extensive, centrally located necrosis and cavitation
have been reported [128]. However, treatment can induce a
marked improvement and sometimes full recovery. The
lesions can also resemble ischemic lesions in the anterior
spinal artery territory [129] or local tumours [130]. Addi-
tional presence of cerebral lesions does not exclude a
diagnosis of NMO. Cerebral T2-/FLAIR hyperintensities
exist in up to 60 % of NMO patients, although they are
often clinically silent, frequently not classically oval-
shaped (as typically seen in MS), and typically not visible
on T1-weighted images [131, 132]. In two recent studies,
58 % and 63 %, respectively, of patients with NMOSD
showed brain lesions and, of these, 18 % and 27 %,
respectively, were considered diagnostic of MS [1, 132].
Brain lesions are generally located close to the ventricles,
in the diencephalon and hypothalamus. Two recent ultra-
high-field MRI studies showed that—as opposed to MS
lesions—NMO lesions in the brain are not characterized by
central veins and that cortical lesions were absent in NMO
[133, 134]; however, extensive lesions and MS-like find-
ings are possible [57, 135–142].
Optical coherence tomography
Optical coherence tomography (OCT) is a rapid and non-
invasive technique for imaging unmyelinated CNS axons
within the retina (the so-called retinal nerve fiber layer,
RNFL). Recent technical advances have facilitated the
high-resolution depiction of deeper retinal layers such as
the ganglion cell layer. OCT is an increasingly popular tool
in neuroimmunological research. Damage (thinning) to the
RNFL in MS patients with and without a history of ON has
been demonstrated by numerous groups. The suitability of
OCT as a means of measuring disease progression and as a
response marker for neuroprotective therapies in MS and
other neurological conditions is currently being investi-
gated [143–150].
A single acute attack of ON causes more severe damage
to the RNFL in NMO than in MS, reflecting the poorer
visual outcome in NMO-associated ON [7, 151, 152].
While MS patients experience progressive reduction of the
RNFL over time compared with healthy controls, accrual
of RNFL loss in NMO seems to be related to clinical
attacks [153–159]. Whether OCT may contribute to NMO
differential diagnosis is currently under investigation [160].
Therapy
A curative treatment for NMO does not exist to date.
Instead, the main treatment goals are:
1. Remission and improvement of relapse-associated
symptoms
2. Long-term stabilization of disease course by means of
relapse prevention
3. Symptomatic therapy of residual symptoms
This review focuses on relapse therapy and intermittent
long-term therapy. For symptomatic treatment recommen-
dations, please see the reviews of MS treatment by de Sa
et al. [161] and Samkoff and Goodmann [162], both pub-
lished in 2011, as the symptomatic management of NMO is
similar.
The rarity of NMO and its frequently severe disease
course hamper the performance of prospective, randomized
controlled trials evaluating treatment efficacy. The rec-
ommendations presented here are thus mainly based on
case reports, retrospective case series, and a few prospec-
tive studies, all of which only meet evidence class III–IV.
Accordingly, several areas of ambiguity exist. In the case
of seronegative NMO, which more often takes a mono-
phasic course [1], it remains unclear whether the treatment
should be the same as that for seropositive NMO. There-
fore, infectious, parainfectious, metabolic, or paraneoplas-
tic causes must definitely be ruled out before considering
immunosuppressive treatments for patients with seronega-
tive NMO. Similarly, no treatment studies focusing on
patients with limited or atypical forms of APQ4-Ab-posi-
tive NMO have yet been performed. Despite this, early
initiation of long-term immunosuppressive therapy to delay
a second relapse is recommended, because such patients
have a high risk of relapse and conversion to typical NMO
J Neurol (2014) 261:1–16 5
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[53, 163]. In most recent case series and retrospective
studies, the efficacy of the investigated therapies was found
to be the same for patients with typical NMO and with
AQP4-Ab-positive NMOSD. In light of this, relapse and
intermittent treatment of APQ4-Ab-positive patients with
limited forms of NMO should follow that of patients with
typical NMO.
Treatment of acute disease attacks
After standard neurological examination and the exclusion
of infection, steroids are applied on five consecutive days
with 1 g methylprednisolone (MP) per day i.v. in combi-
nation with a proton pump inhibitor and thrombosis pro-
phylaxis [164]. In the case of a confirmed diagnosis of
NMO, and depending on severity of the attack, an oral
steroid tapering period should be considered.
If the patient’s condition does not sufficiently improve
or the neurological symptoms worsen, therapeutic plasma
exchange (TPE, five to seven cycles) can be performed
[165–169]. Notably, TPE was effective both in seropositive
and in seronegative patients with NMOSD in some studies
[166, 170]. Early initiation of TPE might be associated
with better clinical outcome [168, 171, 172]. In some cases,
e.g., if contraindications for TPE exist, a second course of
steroids can be applied at a higher dosage of up to five
times 2 g MP [173, 174]. In a retrospective review of 10
patients treated with intravenous immunoglobulins (IVIg)
for acute relapses because of lack of response to steroids
with/without TPE, improvement was noted in about 50 %
of patients [175].
If the patient is known to have responded well to TPE
during earlier attacks and the present attack is severe, TPE
can also be considered as a first measure. Immunoadsorp-
tion is an option for patients with contraindication for TPE,
such as hypersensitivity reactions, or if TPE is not avail-
able [176]; however, whether the treatment has the same
therapeutic efficacy as TPE has not been investigated to
date.
Long-term treatment of NMO
As NMO takes a relapsing course in most cases, with often
incomplete recovery and rapid accumulation of neurolog-
ical deficits, long-term immunosuppressive treatment
should be initiated once the diagnosis of NMO has been
confirmed. This also applies to APQ4-Ab-negative NMO
patients with a severe first relapse and incomplete remis-
sion. However, as seronegative NMO more often follows a
monophasic course, it may be justified to taper immuno-
suppressive therapy after some years of disease stability
and after careful assessment of the risks and benefits in this
group of patients.
Data on the long-term treatment ([5 years) of NMO are
sparse, all retrospective, and mainly concern azathioprine
(AZA) and rituximab (RX). Accordingly, AZA and RX are
currently the most widely used first-line therapies in NMO.
No studies comparing the efficacy of these two therapies
have been published.
The following section discusses the currently most
widely used therapy regimens and reports on new and
emerging NMO therapies.
Azathioprine
Several studies, including a large retrospective review of
99 patients with NMO/NMOSD, have shown AZA to
reduce relapse rate and ameliorate neurological disability
in NMO [100, 177, 178]. A dosage regimen of 2.5–3 mg/
kg body weight/day orally with monitoring of hematologic
parameters and liver enzymes is recommended. The lym-
phocyte count should decrease to between 600 and 1,000/ll
with AZA therapy and the mean erythrocyte volume should
increase by about 5 % from baseline [177]. If the treatment
response is lacking or side effects present, the dose should
be adjusted or, if necessary, a different treatment should be
applied. As the treatment may only take full effect after
3–6 months, it should initially be combined with oral ste-
roid therapy (1 mg/kg body weight/day), as oral steroids
have been shown to suppress disease activity in NMO [14,
179]. Blood cell count and liver enzyme monitoring are
mandatory. Thiopurine methyltransferase enzyme activity
(TMTP) testing can be performed before AZA therapy, if
available, since patients with low activity may be at higher
risk for severe side effects [180].
Rituximab
B cell depletion with RX has been demonstrated as effective
in the treatment of NMO in several clinical case series and
retrospective analyses [100, 102, 181–185]. Although the
patients in these studies generally had already received one
or more previous treatments, RX is now increasingly also
used in treatment-naı¨ve NMO patients with high disease
activity. Thus, RX is another option for first-line treatment
in NMO/NMOSD and for patients who have not responded
to previous immunosuppressive therapy (e.g., AZA).
RX treatment can be initiated using one of two different
regimens: either two 1 g infusions of RX at an interval of
2 weeks or four weekly 375 mg/m2 body surface area (BSA)
applications. To prevent infusion-related side effects, pre-
medication (1 g paracetamol, 100 mg prednisolone, 4 mg
dimethindene maleate i.v.) should be dispensed. Addition-
ally, the infusion should be administered at a sufficiently
slow speed and monitored. Increasing evidence shows that
incomplete B-cell depletion and/or B-cell repopulation is
6 J Neurol (2014) 261:1–16
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associated with relapse risk in NMO [100, 102, 183, 186].
Because most patients remain B-cell deficient for 6 months
after RX treatment, re-dosing every 6 months is considered
to be an adequate retreatment frequency [183]. CD19/20-
positive B cells and/or CD27? memory cells may be used as
surrogate markers for treatment monitoring and re-dosing
[100, 102, 183, 185]. Whether long-term RX treatment at
lower doses does in fact suppress disease activity, as sug-
gested by first patient therapy cohorts and recent investiga-
tions [185–187], requires further investigation. Individual
patients with NMO have been treated up to eleven times with
RX without major side effects and with an acceptable safety
profile. Cases of progressive multifocal leukoencephalopa-
thy (PML) have been reported in patients with cancer and
rheumatological diseases treated with RX, mostly in com-
bination with other immunosuppressive therapies. To date,
no incidents of progressive PML have been reported in NMO
patients during RX therapy. However, more data on the
efficacy and safety of RX treatment in NMO are required.
Mycophenolate mofetil
In a retrospective analysis of 24 patients, treatment with
mycophenolate mofetil (MMF) (median dose 2,000 mg/
day, ranging between 750 and 3,000 mg) was associated
with a reduction in relapse frequency and stable or reduced
disability in patients with NMOSD. Half the patients in the
study had previously been treated with AZA [188]. The
treatment effect occurs more rapidly for MMF than for
AZA. In patients experiencing side effects or poor response
to AZA, MMF is recommended as an alternative treatment.
PML has not yet been observed in NMO patients during
treatment with MMF, but has been encountered in trans-
plant recipients [189].
Immunoglobulins
Individual case reports and a 2012 case series have shown
that high-dose IVIg are potentially beneficial [190–192].
For example, a case series of eight Spanish NMO patients
showed positive results using bimonthly IVIg treatment
(0.7 g/kg body weight/day for 3 days) for up to 2 years
[192]. Thus, IVIg therapy is suggested as an alternative for
patients with contraindication to one of the other treatments
or, particularly, in children.
Mitoxantrone
Two recent observational studies [193, 194] have reported
a 75–80 % reduction in relapse rate during treatment with
mitoxantrone (treatment duration up to 22 months),
underlining prior reports on the efficacy of mitoxantrone in
NMO. A dose of 12 mg/m2 BSA of mitoxantrone was
administered i.v. monthly for 3–6 months, followed by
infusions of 6–12 mg/m2 every 3 months. The maximum
dose of mitoxantrone was 100–120 mg/m2 BSA. Whether
other regimes (e.g., sole quarterly infusions, frequently
used in MS) are as efficacious is not known. Due to the side
effects (cardiotoxicity, therapy-related acute leukemia
[195–197]) and the limited duration of the therapy, we
recommend mitoxantrone as a second-line therapy when
the treatments described above fail or cannot be applied.
As for MS, we recommend that the maximum cumulative
dose should not exceed 100 mg/m2 BSA. In individual
cases, treatment with up to 140 mg/m2 BSA can be
administered by a physician experienced in the therapy, but
only if a stringent risk–benefit analysis is performed and
cardiac function is monitored throughout the treatment.
Cyclophosphamide
While preliminary evidence from a number of case studies
(AQP4-Ab-positive and -negative; systemic lupus erythe-
matosus- and Sjo¨gren’s syndrome-associated; daily oral
dose in one, IV pulse in six, immunoablative in one;
combination with steroids, IVIg, or AZA in all) suggested a
possible treatment response to cyclophosphamide (CYC)
[100, 198–201], a recent retrospective analysis of seven
Brazilian NMO cases (pulsed IV CYC) failed to show such
effect [202]. In another study, three of four patients treated
with pulsed IV CYC had to be switched to methotrexate
later due to treatment failure [203]. In light of this, CYC is
only recommended when other immunosuppressive thera-
pies fail or are not available. The treatment may be applied
in immunoablative doses (2,000 mg/day for 4 days) or at a
dose of 600 mg/m2 BSA per administration (together with
uromitexan). The dose should be adjusted according to
changes in the total leukocyte count, and CYC should be
applied only under the supervision of an experienced
physician.
Interferon-beta/glatiramer acetate
Interferon (INF)-beta should not be used in patients with
NMO, as several retrospective studies have shown that
INF-beta treatment frequently results in NMO disease
exacerbation [100, 204–208]. Glatiramer acetate has not
been shown to have detrimental effects in NMO patients to
date; with only three cases reported, however, insufficient
data exist on glatiramer acetate as NMO treatment [100,
209, 210].
Methotrexate
In a retrospective study of 14 AQP4-Ab-positive patients,
treatment with methotrexate, mainly prescribed as a
J Neurol (2014) 261:1–16 7
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second-line drug, was associated with a significant
decrease in the median annualized relapse rate (ARR) and
was relatively well-tolerated. After exclusion of relapses
within the first 3 months of treatment or on subtherapeutic
doses, the proportion of relapse-free patients was 64 %.
Disability stabilized or improved in 79 % [211]. In 13 of 14
cases, however, concomitant immunosuppression with oral
prednisolone (n = 11), rituximab (n = 1), or tacrolimus
(n = 1) was applied, and the impact of this remains
unclear. Treatment with methotrexate and prednisone also
resulted in disease stabilization in a smaller and less well-
documented retrospective case series (n = 7) [203], and in
a pediatric patient on methotrexate monotherapy [37].
Natalizumab
The treatment of NMO with natalizumab should be avoi-
ded; a recent retrospective study reported clinical deterio-
ration after natalizumab treatment in five NMO patients
initially misdiagnosed with MS [212]. In line with this,
Barnett et al. [213] and Jacob et al. [214] have also
described natalizumab treatment as causing disease exac-
erbation in NMO patients.
Fingolimod
Min et al. [215] reported a patient who had been diagnosed
with MS due to an MS-typical brain MRI (which met the
criteria of Barkhof et al.), but without OCB and with a
normal IgG index. The patient had been enrolled in a
clinical trial with fingolimod after experiencing relapses
during 2 years of INF-beta treatment. Clinical deterioration
and increased MRI activity was found 2 weeks after initi-
ation of fingolimod. Diagnosis re-evaluation showed anti-
AQP4 antibodies, indicating NMOSD, and determined that
the patient met the American–European Consensus Group
Criteria (US-EU criteria) for Sjo¨gren’s syndrome, based on
anti-SSA antibody detection, a positive Schirmer’s test,
and a lip biopsy with focal lymphocytic sialoadenitis.
Combination therapies
Combination therapy is a potential option for NMO
patients who have a refractory course. Oral steroids com-
bined with AZA led to a decrease in ARR in two more
recent studies [177, 178]. Similarly, methotrexate in com-
bination with oral steroids resulted in disease stabilization
in two studies [203, 211]. Another recent study showed that
cyclosporin A in combination with low-dose oral steroids is
effective in NMO patients [216]. Methotrexate may be also
combined with RX therapy as in rheumatoid arthritis.
Individual case reports have also shown that intermittent
plasmapheresis combined with immunosuppressive treat-
ment reduces attacks of NMO [217].
Anti-IL-6 therapy and other new therapies
Recent reports have suggested that IL-6 plays a role in
NMO, contributing to the persistence of NMO-IgG-pro-
ducing plasmablasts in patients with NMO [218]. The
hypothesis has been lent weight by studies showing a
favorable effect of the IL-6 receptor-blocking antibody
tocilizumab, already licensed for therapy of rheumatoid
arthritis, in NMO patients who have failed to respond to
other therapies [219–221]. Thus, tocilizumab may be
another therapeutic option for such patients.
The monoclonal antibody eculizumab, which is directed
against the complement component 5, showed considerable
efficacy in a small, open-label study of 14 NMO/NMOSD
patients with disease activity [222, 223]. Of the 14 treated
patients, 12 remained relapse-free and two showed disease
activity. Apart from meningococcal sepsis and sterile
meningitis in one patient approximately 2 months after the
first eculizumab infusion, no other drug-related serious
adverse events were reported. However, confirmation from
larger, phase III studies is needed; moreover, broad
administration of eculizumab would be hampered by its
presently exorbitant cost.
Recent experimental strategies, which showed some
beneficial effect in animal models in vitro and in vivo,
include the use of competitive, non-pathogenic AQP4-
specific antibodies (e.g., aquaporumab) [224, 225], neu-
trophil elastase inhibitors [226], antihistamines with
eosinophil-stabilizing actions [227], and enzymatic AQP4-
IgG deglycosylation or cleavage [228, 229].
An isolated case report showing that autologous hema-
topoietic stem cell transplantation (AHSCT) failed to pre-
vent further relapses in a NMO patient raised concerns
about the treatment’s efficacy in NMO. However, an
ongoing AHSCT trial involving 10 NMO patients is
expected to shed light on whether some patients do benefit
from the therapy [230]. Alemtuzumab, a B- and T-cell-
depleting antibody previously used in MS trials with
favorable outcome, did not show beneficial effects when
used in individual NMO patients [220, 231].
Summary for treatment recommendations
Based on the currently available evidence as summarized
above, the NEMOS group gives the following treatment
recommendations:
The frequently severe disease course of NMO calls for
prompt initiation of immunosuppressive treatment once the
8 J Neurol (2014) 261:1–16
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diagnosis of NMO or AQP4-Ab-positive NMOSD has been
confirmed, with azathioprine or rituximab as first-line
treatment (see Fig. 1). In children or in patients with con-
traindications to immunosuppressive therapies, IVIg may
be used as first-line therapy. In patients with NMOSD who
are AQP4-Ab negative, therapy initiation depends on the
severity and remission of the first relapse and the clinical
course.
In the case of side effects or poor response, treatment can
be switched from azathioprine to rituximab or vice versa, or
to mycophenolate mofetil, methotrexate, or mitoxantrone.
If disease progression occurs and if the above treatments
fail, combination therapy or newer agents such as toc-
ilizumab may be applied. Treatment with interferon-beta,
natalizumab, and fingolimod should be avoided. How and
whether treatment with the recently approved therapies for
MS, teriflunomide and fumaric acid, influences the disease
course in NMO patients remains to be elucidated.
In general, physicians must inform patients about the
risks of side effects, such as malignancy, infertility, cyto-
toxicity and myelotoxicity, infections including PML,
vaccination issues, and the need for contraception before
initiating immunosuppressive therapies. Tests for preg-
nancy and chronic infections (HIV, hepatitis B and C)
before treatment commencement are recommended.
Future directions
The pathogenesis, diagnosis, and treatment of NMO are
rapidly expanding research areas, as reflected by the steep
increase in the number of publications on NMO since
AQP4 antibodies were first described. Consequently, we
expect major advances in all three areas over the next few
years. Research on pathogenesis has progressed to studying
the role of T-cells, neutrophils, eosinophils, and other
cellular components of the immune system [27, 227, 232–
234]. Several new potential therapeutic approaches have
resulted from recent insights in NMO pathogenesis,
including complement and neutrophil elastase inhibition
[226] (eculizumab, sivelestat [235]), and the blocking of
antibodies to AQP4 with monoclonal antibodies (aquapo-
rumab), among others. The challenges in finding new and
better medicines for NMO are the rareness of the disease
and the unfavorable prognosis in many cases, which make
clinical studies with placebo groups difficult. Although
designing meaningful and clinically relevant NMO therapy
studies is laborious, these trials will eventually increase our
options for treating NMO.
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Combination therapy*
Tocilizumab
Third-line therapy
Azathioprine Rituximab 
(IVIg°)
First-line therapy
Mycophenolate Mofetil, Mitoxantrone, Methotrexate 
Second-line therapy
*Includes:
a) combination of steroids plus cyclosporin A or methotrexate or azathioprine 
b) combination of immunosuppression plus intermittent plasma exchange
c) combination of rituximab with methotrexate or intravenous immunoglobulins (IVIg)
°IVIg in patients with contraindication to immunosuppression, particularly in children 
Fig. 1 Long-term therapy of
NMO
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